New hope for stem cell transplant patients: combo therapy targets severe GVHD
NCT ID NCT07340723
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding ruxolitinib to standard steroids works better than steroids alone for grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplant. About 168 adults who have had a first stem cell transplant for blood cancer and develop GVHD within 100 days will take part. The main goal is to see if the combination improves response at day 28.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A bedtime kit for the hospital: can ear plugs and a lightbox help young transplant patients sleep?
- New drug shows promise in controlling transplant complications
- Placenta cell therapy shows promise for tough transplant complication
- Blood test may spot deadly transplant complication earlier
- Simple blood test may predict deadly transplant complication
- New hope for kids with sickle cell: stem cell transplant from mismatched blood type donors